PHILADELPHIA — (July 10, 2024) — The Wistar Institute (“Wistar”) is pleased to announce a research collaboration with Accelerated Biosciences Corp. (“Accelerated Bio”) aimed at creating a groundbre…
PHILADELPHIA — (July 1, 2024) —The Wistar Institute is pleased to announce the appointment of Jozef Madzo, Ph.D., to the faculty as an assistant professor and Director of Bioinformatics. Dr. Madzo …
PHILADELPHIA — (Thursday, June 27, 2024) — The Wistar Institute’s Noam Auslander, Ph.D., assistant professor in the Molecular and Cellular Oncogenesis Program at the Ellen and Ronald Caplan Cancer …
PHILADELPHIA — (June 18, 2024) — The Wistar Institute received a $10 million donation from an anonymous donor who previously committed $20 million to support Wistar’s new Center for Advanced Therap…
PHILADELPHIA — (June 04, 2024) — Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form of kidney cancer with few treatment options; even with new immunotherapies, only around one in 10 …
PHILADELPHIA — (May 28, 2024) — The Wistar Institute’s Paul M. Lieberman, Ph.D., and lab team led by senior staff scientist and first author, Samantha Soldan, Ph.D., have demonstrated how B cells i…
The West Philadelphia Skills Initiative, The Wistar Institute, PIDC, The Chamber of Commerce for Greater Philadelphia, Iovance Biotherapeutics, and Integral Molecular Began Joint Recruitment May 21…
PHILADELPHIA — (May 14, 2024) — The Wistar Institute was awarded a $649,971 grant from the National Science Foundation (NSF) to support the continued expansion of its award-winning Biomedical Techn…
PHILADELPHIA — (May 3, 2024) — The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma — a serious and often fatal brain cancer…
PHILADELPHIA — (Tuesday, April 30, 2024) — Hepatocellular carcinoma (HCC), or liver cancer, is an aggressive malignancy with limited treatment options. An immunologically cold cancer — meaning the …
